Debiopharm International SA: Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first

Related Keywords

Ljubljana ,Slovenia General ,Slovenia ,Taiwan ,Switzerland ,United States ,Boston ,Massachusetts ,America ,Swiss ,Hamzeh Abdul ,Rafael Rosengarten ,Miha Stajdohar ,Andrea Vuturo ,Health Ventures ,Regeneron Pharmaceuticals ,Debiopharm Innovatoin Fund Taiwania Capital ,Vuturo Group For Genialis ,Debiopharm Innovation Fund ,Head Of Communications ,Debiopharm Innovatoin Fund ,Taiwania Capital ,First Star Ventures ,Redalpine Venture Partners ,Hamzeh Abdul Hadi ,Geniali Board ,Investment Director ,Debiopharm Innovation ,Clinical Oncology ,Managing Partner ,Precision Oncology Xchange ,Companion Diagnostics Xchange ,Oncxerna Therapeutics ,National Development Fund ,Executive Yuan ,Innovation Fund ,Debiopharm ,Nternational ,Genialis ,Raises ,Build ,Linical ,Biomarkers ,Redict ,Patient ,Response ,